At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
BMS-986036 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
In Brief
A Phase 2 clinical trial evaluating BMS-986036 and Placebo for Hepatic Cirrhosis and 3 related conditions. Completed, enrolled 155 participants across 91 sites in 2 countries.
Detailed Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
CountriesJapan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionOct 2020
Study CompletionSep 2021
TodayJul 2026
First PostedApr 3, 2018
Enrollment StartJun 12, 2018
Primary CompletionOct 8, 2020
Study CompletionSep 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.2 years ago
Interventions
BMS-986036drug
Specified dose on specified days.
Placeboother
Specified dose on specified days.